MORPHINE SULPHATE (Actimorph orodispersible tablets)
Clinical Indication
Use within palliative care to avoid escalation to subcutaneous preparations particularly in patients with impaired swallow and/or intestinal absorption
Comments
New formulation (May 2025).
Date of classification
May 2025
Green
Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.